Value-Based Care GTM

Translate the contract into a financeable service.

I would underwrite the offer in three steps. First, specify the clinical or operational mechanism: which population, which preventable failure and which service changes the pathway. Second, map the effect through the actual contract, including attribution, quality conditions, benchmark design and reconciliation. Third, compare the buyer’s expected receipts and avoided costs with the full cost and cash timing of delivery. Each step can invalidate a commercially attractive headline.

The pilot must distinguish delivery evidence from outcome evidence. A short implementation can establish whether eligible patients are reached, appointments occur and exceptions are resolved. It may not establish a credible reduction in annual medical spending. I would price and evaluate that initial work for what it can demonstrate, while defining the comparison and observation period needed for any later outcome-based claim.

The commercial structure should allocate risk to the party able to influence it. A service provider can accept responsibility for defined staffing, response and completion obligations. It may have little control over attribution changes, benefit design or care delivered elsewhere. Performance incentives become more credible when controllable obligations and external exposure are explicit, rather than compressed into a broad guarantee of savings.

My expansion decision would turn on whether the service remains useful and financeable under a less favorable settlement. If the business depends entirely on an optimistic benchmark or an unproven utilization effect, I would narrow the commitment or secure prospective support for essential delivery. A durable value-based offer makes the care model, contract and capital requirement intelligible to all parties before scaling.